Video
Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma
Author(s):
Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.
Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.
In the OPTiM trial, patients were randomized to receive T-VEC or a subcutaneous GM-CSF. The primary endpoint was durable response rate, which was reported previously, explains Andtbacka. Patients who received T-VEC acheieved a high durable response rate.
A secondary endpoint of this study was overall survival which was met in this patient population, states Andtbacka.
<<<
